Remission rates of select mental illness and substance use disorders in India
pdf

Keywords

Remission rate, Mental illness and substance use disorder, Epidemiology, Prevalence, Incidence

How to Cite

1.
A.M. A. Remission rates of select mental illness and substance use disorders in India. J Basic Clin Appl Health Sci [Internet]. 2019Mar.21 [cited 2019May21];2(1):14-. Available from: https://jbcahs.org/journal/article/view/141

Abstract

Background: There are very few literature evidence studying the remission rates among mental illness and substance use disorders (MISUD) in India. Knowledge of the remission and its characteristics can help to draw better policies for mental health care delivery in India.

Method: Using the Global Burden of Diseases, 2016 approach and employing the DisMod-MR – 2.1.6 mathematical modelling, prevalence, incidence and remission rates of 4 substance use disorders (alcohol, opioid, cocaine and cannabis), schizophrenia, major depressive disorder, bipolar disorder, anxiety disorders and conduct disorder were studied.

Results: Within the mathematical model confines the prevalence, incidence characteristics of MISUDs based on age and gender are presented. The remission rate per person year ranged from 0.015 to 1.46 for different MISUD. Gender had significant on the model for anxiety disorders, conduct disorders, opioid and alcohol use disorder. The effect of age on the model are described in detail

Conclusions: The outcome of the study indicates the remission rates of MISUDs are highly variable. Remission rates significantly varies between age and gender. Based on these inputs, customized and targeted MISUDs therapies may be designed for better remission. The study also underlines the need for further large scale research efforts required for studying and reporting natural history of MISUDs from India.

pdf

References

1. Gururaj G, Varghese M, Benegal V, Rao GN, Pathak K, Singh LK, et al. National Mental Health Survey of India, 2015-16: Summary. Bengaluru: National Institute of Mental Health and Neuro Sciences, NIMHANS Publication No. 128; 2016, Bengalaru, 1st Edition.
2. Bland RC, Newman SC, Orn H. Age and remission of psychiatric disorders. Can J Psychiatry 1997;42:722-9.
3. Roy J, Stewart WF. Methods for estimating remission rates from cross-sectional survey data: Application and validation using data from a national migraine study. Am J Epidemiol. 2011;173:949-55.
4. Rehm J, Mathers C, Popova S, Thavancharoensap M, Teerwattanaanon Y, Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet. 2009; 373:2223-33.
5. Baxter AJ, Vos T, Scott KM, Ferrari AJ, Whiteford HA. The global burden of anxiety disorders in 2010. Psychol Med 2014;44:2363-74.
6. Ferrari AJ, Stockings E, Khoo J, Erskine HE, Degenhardt L, Vos T, Whiteford HA. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disorders. 2016;18:440-50.
7. Degenhardt L, Ferrari AJ, Calabaria B, Hall WD, Norman RE, McGrath J et al., The global epidemiology and contribution of cannabis use and dependence to the global burden of disease:Results from the GBD 2010 Study. PLoS ONE 8(10): e76635. doi:10.1371/journal.pone.0076635
8. Erskine HE, Ferrari AJ, Polanczyk GV, Moffitt TE, Murray CJL,Vos T et al., The global burden of conduct disorder and attentiondeficit/hyperactivity disorder in 2010. J Child Psychol Psych. 2014;55:328-36.
9. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJL et al., Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med 10(11): e1001547. doi:10.1371/journal.pmed.1001547
10. Degenhardt L, Baxter AJ, Lee YY, Hall W, Sara GE, Johns N et al., The global epidemiology and burden of psychostimulant dependence: Findings from the Global Burden of Disease Study 2010. Drugs Alcohol Depend. 2014;13:36-47.
11. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci. 2000;250;274-85.
12. Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance use disorders: An analysis from the global burden of disease. PLoS ONE 10(2): e0116820. doi:10.1371/journal.pone.0116820
13. Charlson FJ, Baxter AJ, Cheng HG, Shidhaye R, Whiteford HA. The burden of mental, neurological, and substance use disorders in China and India: a systematic analysis of community representative epidemiological studies. Lancet 2016;388:376-89.
14. Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD et al., Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382:1564-74.
15. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211-59.
16. Jacob KS. Indian Psychiatry and classification of psychiatric disorders. Indian J Psychiatry 2010;52:S104-9.
17. Baxter AJ, Patton G, Scott KM, Degenhardt L, Whiteford HA. Global epidemiology of mental disorders: What are we missing? PLoS ONE 8(6): e65514. doi:10.1371/journal.pone.0065514
18. Relationship among prevalence, incidence rate, and average duration of disease. Available from: http://sphweb.bumc.bu.edu/otlt/MPHModules/EP/ EP713_DiseaseFrequency/EP713_DiseaseFrequency7.
html [accessed on 2017 Sep 23]
19. McIntyre RS, Fallu A, Konarski JZ. Measurable outcomes in psychiatric disorders: remission as a marker of wellness. Clin Therap. 2006;28:1882-91.
20. Rubio JM, Olfson M, Villegas L, Peres-Fuentes G, Wang S, Blanco C. Quality of life following remission of mental disorders: Findings from the national epidemiologic survey on alcohol and related condition. J Clin Psychiatry. 2013;74:e449.
21. Haro JM, Novick D, Bertsch J, Karagianis J, Dossenbach M, Jones PB. Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study. Br J Psychiatry. 2011;199:194-201.
22. Hajda M, Kamaradova D, Latalova K, Prasko J, Ociskova M, Mainerova B et al., Self-stigma, treatment adherence, and medication discontinuation in patients with bipolar disorders in remission – a cross sectional study. Act Nerv Super Rediviva. 2015;57:6-11.
23. Ramasubramanian C, Mohandoss AA, Namasivayam RK. Employability of mentally ill persons in India: A self-report-based population study. Ind Psychiatry J. 2016;25:171-8.
24. Mohandoss AA, Rooban T. An audit of Indian health Insurance claims for mental illness from pooled insurance information bureau’s macroindicator data. Indian J Psychol Med. 2017;39:254-61.
25. Lanata A, Valenza G, Nardelli M, Gentili C, Scilingo EP. Complexity index from a personalized wearable monitoring system for assessing remission in mental health. IEEE J Biomed Health Inform. 2015;19:132-9.
26. Mohandoss AA, Thavarajah R. Contribution of Indian psychiatrists to PubMed listed mental health literature during 1995–2013: An exploratory study. Indian J Psychol Med. 2016;38:302-8.
27. Mohandoss AA, Thavarajah R. Contribution and performance of Indian psychiatrists and a Pan-Indian Psychiatry Journal to Mental health literature during 2010-14. J Scientometric Res 2016;5:100-05.

Downloads

Download data is not yet available.